Company news

Latigo Biotherapeutics, Inc. news

Latest news releases, newest first.

View company

Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

November 5, 2026

Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth

November 5, 2026

Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November

November 3, 2026

LTGO: Onzotrigine delivers rapid, superior pain relief with strong opioid-sparing potential in late-stage trials

September 3, 2026

Latigo Biotherapeutics Price Target Announced at $36.00/Share by Leerink Partners

September 1, 2026

Latigo Biotherapeutics Ups IPO to 19.2 Million Shares

August 7, 2026

Decks